Outset Medical, Inc. (OM)
Last Price$10.54.4%
Market Cap$553.3M
OM Rating
OM Quality rating performance
OM Intrinsic Value
Key Highlights:
As of Mar 24, 2025 OM Relative Value is $15.3, which is undervalued by 45.9%, compared to current share price of $10.5.
As of Mar 24, 2025 OM DCF Value is N/A, which is undervalued by N/A, compared to current share price of $10.5.
OM Share Price History
1W 1,714.6%
1M 1,186.0%
6M 1,832.2%
YTD 86.0%
1Y 409.2%
3Y (74.9%)
5Y (82.7%)
10Y (82.7%)
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
OM Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$553.3M
$401.7M
$113.7M
($117.2M)
Shares Outstanding
53M
Employees
354
Growth (CAGR)
49.8%
10.0%
(47.40%)
(58.21%)
Profitability
33.9%
(99.7%)
(112.6%)
(102.3%)
(103.1%)
91.6%
Intrinsic Value
$15.3 (45.9% undervalued)
N/A
$15.3
$108.9
(100.0%)
(2,656.2%)
Valuation (LTM)
Return on Capital
Financial Health
($151.5M)
1.3x
(4.7x)
26.7%
Dividends
Earnings
Aug 05, 2025
BEAT by 3.4%
BEAT by (16.2%)
6 Beat & 4 Miss
OM Stock Financials
OM Income Statement Metrics
Annual
Quarterly
LTM
OM Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($116.3M) -11.5% YoY
Capital Expenditure (CAPEX)
($912.0K) -73.5% YoY
Free Cash Flow (FCF)
($117.2M) -13.1% YoY
OM Income Statement Overview
Annual
Quarterly
LTM
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$113.7M (12.8%) YoY
Cost of revenue
$75.1M (25.9%) YoY
Operating
expenses
$151.9M (23.6%) YoY
Other: $128.0M
OM Balance Sheet Overview
Annual
Quarterly
LTM
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$275.8M
Current assets ($258.2M, 93.6% of total)
$158.7M (57.5%)
$35.6M (12.9%)
Other current assets
$63.9M (23.2%)
Non-current assets ($17.6M, 6.4% of total)
$0.0 (0.0%)
$12.1M (4.4%)
$0.0 (0.0%)
Other non-current assets
$5,501.0K (2.0%)
Financial position
($151.5M)
Cash & Short-term
Investments
Total Debt
OM Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
OM Earnings Surprises
Crunching data... Almost there!
OM Dividends
OM Dividend Yield
Crunching data... Almost there!
OM Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with OM
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$553.3M | 5.0 | $15.3 45.9% undervalued | 409.2% | $113.7M | ($117.2M) | (12.8%) | (103.1%) | 33.9% | (109.3%) | 26.7% | |
$220.3B | 7.1 | $178.0 39.9% undervalued | 18.0% | $42.0B | $6,351.0M | 4.6% | 15.1% | 55.6% | 25.3% | 31.4% | |
$151.1B | 6.8 | $36.3 64.7% overvalued | 52.6% | $16.7B | $2,438.0M | 17.6% | 14.6% | 67.0% | 8.0% | 50.7% | |
$142.6B | 6.6 | $299.2 20.1% overvalued | 7.6% | $22.6B | $3,487.0M | 10.2% | 15.4% | 62.8% | 10.4% | 65.9% | |
$115.6B | 6.4 | $116.8 29.6% undervalued | 11.1% | $33.2B | $5,467.0M | 2.7% | 16.5% | 62.9% | 7.4% | 53.6% | |
$42.1B | 6.1 | $54.4 23.8% overvalued | (23.4%) | $5,724.3M | $289.9M | (4.7%) | 5.1% | 78.4% | 21.6% | 7.0% | |
$30.1B | 7.3 | $39.2 48.0% overvalued | (46.2%) | $4,033.0M | $630.7M | 11.3% | 15.6% | 60.4% | 21.7% | 120.3% | |
$23.6B | 5.3 | $68.3 168.1% undervalued | 32.4% | €18.0B | €1,145.0M | (0.8%) | 6.4% | 43.1% | (4.2%) | 63.4% | |
$22.5B | 5.8 | $177.2 59.3% undervalued | (12.3%) | $7,678.6M | $1,132.4M | 3.8% | 14.7% | 66.0% | 6.3% | 43.0% | |
$22.0B | 6.4 | $194.8 12.7% overvalued | 2.1% | $5,398.4M | $751.4M | (0.2%) | 13.9% | 44.7% | 8.2% | 35.6% | |
$19.2B | 7.9 | $104.9 61.7% overvalued | 66.3% | $1,900.3M | $303.0M | 12.0% | 15.9% | 76.4% | 26.9% | 6.9% |
FAQ
What is Outset Medical, Inc. (OM) stock rating?
As of today, Outset Medical, Inc. has a stock rating of 5 (out of 10), which is considered Good.
is Outset Medical, Inc. (OM) a good stock to buy?
As of today, Outset Medical, Inc. has a Good stock rating, which is 45.9% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 3.2%.